In a recent study by Charles D. Nichols at the Department of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center in New Orleans USA it was shown that Psychedelics have potent anti-inflamitory effects even with sub-perceptual doses (microdosing).
Psychedelics have been under a broad range of new studies as excitement and legal shifts have made it possible to conduct scientific studies on these compounds again. Most of these studies are focused on the psychoactive effects of taking these compounds and how they may be effective treatments for various mental conditions such as depression, addiction or PTSD.
However in this study it was shown that psychedelics can both prevent and reduce inflammation. This discovery opens the development of psychedelics as a potential therapeutic for human inflammatory diseases.
Much more study is needed for specific diseases and the effects psychedelics may have on them. But this widens the potential for further studies to investigate sub-behavioral psychedelic doses effects on allergies, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, preperfusion injury and transplant rejection.
The global anti-inflammatory drug market was valued at $93.9B annually in 2019. The potential impact of a new class of small molecule, potent anti-inflammatory that is highly bio-available and can pass the blood-brain barrier is exciting.
We’re looking forward to seeing the results of future research in this avenue of discovery. Opening up an entirely new set of potential use cases for this powerful set of psychedelic compounds.